EC 18 - Enzychem Lifesciences

Drug Profile

EC 18 - Enzychem Lifesciences

Latest Information Update: 09 Mar 2016

Price : $50

At a glance

  • Originator Enzychem Lifesciences Corporation
  • Class Antineoplastics; Chemoprotectants
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Macrophage stimulants; Neutrophil stimulants; Tumour protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neutropenia
  • Preclinical Sepsis

Most Recent Events

  • 01 Dec 2015 Enzychem completes a phase I trial in Neutropenia (In volunteers, Chemotherapy-induced) in South Korea (PO) (NCT02532712)
  • 01 Dec 2015 Enzychem Lifesciences completes a phase I trial in Neutropenia (In volunteers, Chemotherapy-induced) in USA (NCT02496143)
  • 01 Oct 2015 Enzychem completes a phase I trial in Healthy volunteers in South Korea (PO, Capsule) (NCT02700360)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top